Abstract

Background: Radiotherapy technology has undergone significant advancements, driven by the pursuit of improved tumor control probabilities and reduced normal tissue complication probabilities. This has been achieved primarily through innovative approaches that prioritize high dose conformity on complex treatment targets. The CONVERAY project introduces a groundbreaking teletherapy system featuring a convergent X-ray beam, which enables highly conformal dose distributions by converging photons to a focal spot, thereby achieving exceptionally high fluence rates. Methods: Customized Monte Carlo subroutines have been developed to simulate particle fluence and associated dosimetry effects for the CONVERAY device. This simulation approach facilitated a detailed, step-by-step characterization of radiation fluence and interaction processes, enabling seamless integration with a conventional clinical linear accelerator head. Key physical properties of the radiation beam have been comprehensively characterized for various CONVERAY configurations, providing a solid foundation for evaluating the corresponding dosimetry performance. Results: Monte Carlo simulations successfully tracked the phase state of the CONVERAY device, characterizing the influence of individual components on convergent photon beam production. Simulations evaluated dosimetry performance, confirming the device's capability to achieve high dose concentrations around the focal spot. Preliminary tests on realistic scenarios (intracranial and pulmonary irradiations) demonstrated promising spatial dose concentration within tumor volumes, while gantry rotation significantly improved dose conformation. Conclusions: This proof-of-concept Monte Carlo study of the CONVERAY prototype provided critical insights into the generation of convergent X-ray beams, validating the device's ability to achieve its primary objective. Notably, simulation results reveal the potential for exceptionally high dose concentrations within complex treatment volumes, demonstrating promising dosimetry performance.